Rosiglitazone aggravates nonalcoholic fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet

Pancreas

Volumn 38, Issue 3, 2009, Pages

  Fernandes Santos, Caroline ^a   Evangelista Carneiro, Rafael ^a   De Souza Mendonca, Leonardo ^a   Barbosa Águila, Márcia ^a   Alberto Mandarim De Lacerda, Carlos ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

GLUT2; High fat high sucrose diet; Islet ypertrophy; Nonalcoholic fatty pancreatic disease; Peroxisome proliferator activated receptors

Indexed keywords

AMYLASE; BEZAFIBRATE; FENOFIBRATE; GLUCAGON; GLUCOSE; GLUCOSE TRANSPORTER 2; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; ROSIGLITAZONE; TRIACYLGLYCEROL LIPASE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY MASS; C57BL 6 MOUSE; CONTROLLED STUDY; DIET RESTRICTION; DISEASE EXACERBATION; DRUG EFFECT; ENZYME ASSAY; EVALUATION; GLUCOSE BLOOD LEVEL; HYPERTROPHY; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; LIPID DIET; MALE; MOUSE; NONALCOHOLIC FATTY PANCREAS DISEASE; NONHUMAN; ORGAN SIZE; PANCREAS DISEASE; PANCREAS ISLET; PANCREATITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEREOLOGY; TREATMENT DURATION; WEIGHT GAIN; ADIPOSE TISSUE; ANIMAL; BLOOD; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; ENERGY METABOLISM; FAT INTAKE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOLOGY; SUGAR INTAKE;

ADIPOSE TISSUE; ANIMALS; ANTILIPEMIC AGENTS; BEZAFIBRATE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIETARY FATS; DIETARY SUCROSE; ENERGY METABOLISM; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MICE; MICE, INBRED C57BL; OBESITY; PANCREATIC DISEASES; PPAR ALPHA; PPAR-BETA; PROCETOFEN; THIAZOLIDINEDIONES; WEIGHT GAIN;

EID: 65549152238     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181987d9d     Document Type: Article

References (47)

1. El-Zayadi AR. Hepatic steatosis: a benign disease or a silent killer. World J Gastroenterol. 2008;14:4120-4126.
2. Lidofsky SD. Nonalcoholic fatty liver disease: diagnosis and relation to metabolic syndrome and approach to treatment. Curr Diab Rep. 2008;8:25-30.
3. Neuschwander-Tetri BA. Fatty liver and the metabolic syndrome. Curr Opin Gastroenterol. 2007;23:193-198.
4. Katz DS, Hines J, Math KR, et al. Using CT to reveal fat-containing abnormalities of the pancreas. AJR Am J Roentgenol. 1999;172: 393-396.
5. Gulcan E, Gulcan A, Ozbek O. Is there a role of pancreatic steatosis together with hypertrigliceridemia on the pathogenesis of diabetes in a patient with type 2 diabetes mellitus? Med Hypotheses. 2007;68: 912-913.
6. Mathur A, Marine M, Lu D, et al. Nonalcoholic fatty pancreas disease. HPB (Oxford). 2007;9:312-318.
7. Chowdhury P, Nishikawa M, Blevins GW Jr, et al. Response of rat exocrine pancreas to high-fat and high-carbohydrate diets. Proc Soc Exp Biol Med. 2000;223:310-315.
8. Desvergne B, Wahli W. Peroxisome proliferatorYactivated receptors: nuclear control of metabolism. Endocr Rev. 1999;20:649-688.
9. Willson TM, Brown PJ, Sternbach DD, et al. The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000;43:527-550.
10. Fruchart JC, Staels B, Duriez P. The role of fibric acids in atherosclerosis. Curr Atheroscler Rep. 2001;3:83-92.
11. Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes. 2005;54:2460-2470.
12. Gallou-Kabani C, Vige A, Gross MS, et al. C57BL/6J and A/J mice fed a high-fat diet delineate components of metabolic syndrome. Obesity. 2007;15:1996-2005.
13. Schreyer SA, Wilson DL, LeBoeuf RC. C57BL/6 mice fed high fat diets as models for diabetes-accelerated atherosclerosis. Atherosclerosis. 1998;136:17-24.
14. Reeves PG, Nielsen FH, Fahey GC Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr. 1993;123:1939-1951.
15. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
16. Mandarim-de-Lacerda CA. Stereological tools in biomedical research. An Acad Bras Cienc. 2003;75:469-486.
17. Jia D, Otsuki M. Bezafibrate, a peroxisome proliferator-activated receptor (PPAR)Yalpha activator, prevents pancreatic degeneration in obese and diabetic rats. Pancreas. 2003;26:286-291.
18. Jia D, Yamamoto M, Otani M, et al. Bezafibrate on lipids and glucose metabolism in obese diabetic Otsuka Long-Evans Tokushima fatty rats. Metabolism. 2004;53:405-413.
19. Walters MN. Adipose atrophy of the exocrine pancreas. J Pathol Bacteriol. 1966;92:547-557.
20. Itai Y, Saida Y, Kurosaki Y, et al. Focal fatty masses of the pancreas. Acta Radiol. 1995;36:178-181.
21. Patel S, Bellon EM, Haaga J, et al. Fat replacement of the exocrine pancreas. AJR Am J Roentgenol. 1980;135:843-845.
22. Sgro C, Escousse A. Side effects of fibrates (except liver and muscle). Therapie. 1991;46:351-354.
23. Brown WV. Expert commentary: the safety of fibrates in lipid-lowering therapy. Am J Cardiol. 2007;99:19C-21C.
24. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology. 2003;38:1008-1017.
25. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004;39: 188-196.
26. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355:2297-2307.
27. Garcia-Ruiz I, Rodriguez-Juan C, Diaz-Sanjuan T, et al. Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice. Hepatology. 2007;46:414-423.
28. Cong WN, Tao RY, Tian JY, et al. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice. Life Sci. 2008;82:983-990.
29. Leclercq IA. Pathogenesis of steatohepatitis: insights from the study of animal models. Acta Gastroenterol Belg. 2007;70:25-31.
30. Goldblatt MI, Swartz-Basile DA, Al-Azzawi HH, et al. Nonalcoholic fatty gallbladder disease: the influence of diet in lean and obese mice. J Gastrointest Surg. 2006;10:193-201.
31. Mathur A, Al-Azzawi HH, Lu D, et al. Steatocholecystitis: the influence of obesity and dietary carbohydrates. J Surg Res. 2008;147: 290-297.
32. Al-Azzawi HH, Mathur A, Lu D, et al. Pioglitazone increases gallbladder volume in insulin-resistant obese mice.J Surg Res. 2006;136:192-197.
33. Pitt HA. Hepato-pancreato-biliary fat: the good, the bad and the ugly. HPB (Oxford). 2007;9:92-97.
34. Yoshikawa H, Tajiri Y, Sako Y, et al. Effects of free fatty acids on beta-cell functions: a possible involvement of peroxisome proliferatorYactivated receptors alpha or pancreatic/duodenal homeobox. Metabolism. 2001;50:613-618.
35. Vandewalle B, Moerman E, Lefebvre B, et al. PPARgamma-dependent and -independent effects of rosiglitazone on lipotoxic human pancreatic islets. Biochem Biophys Res Commun. 2008;366:1096-1101.
36. Braissant O, Foufelle F, Scotto C, et al. Differential expression of peroxisome proliferatorYactivated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology. 1996;137:354-366.
37. Inoue I, Itoh F, Aoyagi S, et al. Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. Biochem Biophys Res Commun. 2002;290:131-139.
38. Yoshikawa H, Tajiri Y, Sako Y, et al. Effects of bezafibrate on beta-cell function of rat pancreatic islets. Eur J Pharmacol. 2001;426: 201-206.
39. Lalloyer F, Vandewalle B, Percevault F, et al. Peroxisome proliferator-activated receptor alpha improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets. Diabetes. 2006;55:1605-1613.
40. Higashiyama H, Billin AN, Okamoto Y, et al. Expression profiling of peroxisome proliferator-activated receptor-delta (PPAR-delta) in mouse tissues using tissue microarray. Histochem Cell Biol. 2007; 127:485-494.
41. Dubois M, Pattou F, Kerr-Conte J, et al. Expression of peroxisome proliferatorYactivated receptor gamma (PPARgamma) in normal human pancreatic islet cells. Diabetologia. 2000;43:1165-1169.
42. Lupi R, Del Guerra S, Marselli L, et al. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion. Am J Physiol Endocrinol Metab. 2004;286:E560-E567.
43. Welters HJ, McBain SC, Tadayyon M, et al. Expression and functional activity of PPARgamma in pancreatic beta cells. Br J Pharmacol. 2004;142:1162-1170.
44. Rosen ED, Kulkarni RN, Sarraf P, et al. Targeted elimination of peroxisome proliferatorYactivated receptor gamma in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis. Mol Cell Biol. 2003;23:7222-7229.
45. Kim HI, Ahn YH. Role of peroxisome proliferatorYactivated receptorYgamma in the glucose-sensing apparatus of liver and beta-cells. Diabetes. 2004;53(suppl 1):S60-S65.
46. Sun Y, Zhang L, Gu HF, et al. Peroxisome proliferatorYactivated receptorYalpha regulates the expression of pancreatic/duodenal homeobox-1 in rat insulinoma (INS-1) cells and ameliorates glucose-induced insulin secretion impaired by palmitate. Endocrinology. 2008;149:662-671.
47. Yajima K, Hirose H, et al. Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice. Am J Physiol Endocrinol Metab. 2003;284: E966-E971.